Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

  • Discontinued
  • GID-TAG479

Documents

Documents created during the development process.

Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant): draft scope for consultation (pre-referral) - January 2014

Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant): provisional matrix (pre-referral) - January 2014